NDC product
Guaifenesin and Dextromethorphan
NDC 0904-7513 · Major Pharmaceuticals
Key facts
| Product NDC | 0904-7513 |
|---|---|
| Proprietary name | Guaifenesin and Dextromethorphan |
| Nonproprietary name | Guaifenesin and Dextromethorphan |
| Substances | GUAIFENESIN, DEXTROMETHORPHAN HYDROBROMIDE |
| Dosage form | SYRUP |
| Route | ORAL |
| Labeler | Major Pharmaceuticals |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| Pharmacologic classes | Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC] and 1 more |
| Marketing start | Feb 10, 2025 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: